ABSTRACT OF THE DISCLOSURE

PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN

The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula (I).




FIG. 1